Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS

Next-generation CRISPR-based gene-editing therapies tested in clinical trials

With the first CRISPR–Cas9 gene therapy now approved, scientists are turning to newer editing technologies to produce safer, faster and better treatments for genetic diseases.
  1. Natalie Healey

    1. Natalie Healey is a freelance writer in London, UK.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Image credit: Denis Pobytov / DigitalVision Vectors / Getty

Going from the laboratory to an approved therapy in 11 years is no mean feat. That is the story of the world’s first approved CRISPR–Cas9 therapy, greenlit by the US Food and Drug Administration in December 2023. Casgevy (exagamglogene autotemcel), from Vertex and CRISPR Therapeutics, aims to cure sickle-cell disease in a ‘one and done’ treatment. Sickle-cell disease causes debilitating pain and organ damage that can lead to life-threatening disabilities and early death. In a clinical trial, 29 of 31 patients treated with Casgevy were free of severe pain for at least a year after receiving the therapy, which highlights the curative potential of CRISPR–Cas9. “It was an incredible, watershed moment for the field of gene editing,” says biochemist Jennifer Doudna, of the Innovative Genomics Institute at the University of California, Berkeley. “It's a huge step forward in our ongoing quest to treat and potentially cure genetic diseases.”

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Medicine 30, 2380-2381 (2024)

doi: https://doi.org/10.1038/d41591-024-00056-8

The Clinical Pipeline is a column on translational and clinical research, from bench to bedside.

References

  1. Jinek, M. et al. Science 337, 816–821 (2012).

    Google Scholar 

  2. Komor, A. et al. Nature 533, 420–424 (2016).

    Google Scholar 

  3. Chiesa, R. et al. N. Engl. J. Med. 389, 899–910 (2023).

    Google Scholar 

  4. Anzalone, A. V. et al. Nature 576, 149–157 (2019).

    Google Scholar 

Download references

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links